Introduction Cetuximab is a monoclonal antibody directed against the epidermal growth factor receptor (EGFR). It is approved in combination with radiotherapy for locally advanced disease and in combination with platinum-based chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
No takes yet. Share an insight, caveat, or question.
Tran et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: